Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. OGI
OGI logo

OGI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.470
Open
1.430
VWAP
1.45
Vol
284.71K
Mkt Cap
194.60M
Low
1.430
Amount
411.88K
EV/EBITDA(TTM)
--
Total Shares
135.14M
EV
320.95M
EV/OCF(TTM)
--
P/S(TTM)
0.94
Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd.
Show More

Events Timeline

(ET)
2026-02-24
06:10:00
Organigram Launches 10 New Products in Australia
select
2026-02-19 (ET)
2026-02-19
06:30:00
Organigram Enters $65.2M Financing Agreement with British American Tobacco
select
2026-02-19
06:20:00
Organigram Enters $65.2 Million Financing Agreement with British American Tobacco
select
2026-02-18 (ET)
2026-02-18
06:20:00
Organigram Acquires Sanity Group for €113.4 Million
select
2026-02-10 (ET)
2026-02-10
06:20:00
Organigram Reports Q1 Adjusted EBITDA of $5.3M
select
2025-12-31 (ET)
2025-12-31
06:10:00
Organigram Expands Investment in Phylos Bioscience to $10 Million
select
2025-12-16 (ET)
2025-12-16
16:20:00
Major US Averages Mixed as Unemployment Rate Rises to 4.6%
select

News

Newsfilter
8.5
03-10Newsfilter
PinnedOrganigram to Hold Special Meeting for Sanity Group Acquisition Approval
  • Acquisition Overview: Organigram plans to acquire all issued shares of Sanity Group for €113.4 million, comprising €80 million in cash and €33.4 million in common or preferred shares, with a 71% premium over the previous day's closing price, reflecting strong market confidence.
  • Financial Growth Potential: Sanity Group's projected net revenue is expected to grow from €9 million in 2023 to €60 million in 2025, with gross margins improving from 15% to 47%, which will significantly enhance Organigram's revenue and profitability, solidifying its market position.
  • European Market Positioning: This acquisition positions Organigram as a leader in Germany, the world's second-largest legal cannabis market, with forecasts suggesting market growth beyond €4.5 billion by 2028, enabling the company to capitalize on rapidly expanding European opportunities.
  • Investor Meeting Details: The shareholder meeting is scheduled for March 30, 2026, in Toronto, with a voting deadline of March 26; Organigram will also provide a telephone conference for shareholders unable to attend in person, ensuring transparency and engagement.
Newsfilter
5.0
03-05Newsfilter
Organigram Launches SHRED Shotz Beverage
  • Product Launch: Organigram introduces SHRED Shotz, a 65ml single-serve cannabis beverage powered by FAST™ technology, designed to deliver effects within 15 minutes, aiming to attract new consumers and expand the beverage category.
  • Brand Expansion: The SHRED brand surpassed $200 million in retail sales in 2025, and this new product launch further solidifies its market leadership while showcasing Organigram's ongoing commitment to innovation.
  • Technological Advantage: The FAST™ nanoemulsion technology allows SHRED Shotz to outperform traditional products in absorption and efficacy, providing up to 50% faster onset times and double the cannabinoid delivery, enhancing consumer experience.
  • Market Strategy: SHRED Shotz is expected to be available at Canadian retailers in Ontario and Atlantic Canada in March 2026, with plans for expansion into other provinces, thereby increasing Organigram's market presence across Canada.
Newsfilter
8.5
02-24Newsfilter
Organigram Launches New Products in Australia
  • Market Expansion: Organigram's launch of Edison and BOXHOT medical cannabis vape and pastille products in Australia signifies an expansion of its international product portfolio, expected to meet rising market demand and enhance its global medical cannabis presence.
  • Product Innovation: The new lineup includes 10 SKUs, with Edison vapes featuring single-strain live terpenes from Canada's top-selling cultivars, aimed at providing consistent dosing and convenient usage, reflecting the company's expertise in non-flower product development.
  • Strategic Partnership: Through its distribution partnership with Leafio, Organigram's products are expected to reach over 4,000 pharmacies, enhancing accessibility and brand influence in the Australian market, thereby driving sales growth.
  • Industry Event: Organigram will debut its new product lineup at the Medical Cannabis Symposium in Brisbane, using this platform to introduce its product portfolio to clinicians and industry participants, further solidifying its leadership position in the medical cannabis sector.
Yahoo Finance
8.5
02-23Yahoo Finance
Weekly Roundup: Cannabis and Psychedelic Sector Developments
  • Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
  • Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
  • Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
  • Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
Benzinga
8.5
02-19Benzinga
Organigram Secures CAD 65.2 Million Investment
  • Investment Confirmation: Organigram Global Inc. confirmed a CAD 65.2 million private placement investment from a subsidiary of British American Tobacco, indicating strengthened financial health and increased market confidence.
  • Financing Details: The financing includes the subscription of 14,027,074 shares at CAD 3.00 per share (totaling CAD 42.08 million) and the exercise of top-up rights for 9,897,356 shares at CAD 2.335854 per share (totaling CAD 23.12 million), culminating in gross proceeds of CAD 65.2 million.
  • Market Reaction: Following the investment confirmation, Organigram's stock rose 8.70% in Thursday's premarket trading, reflecting investor optimism about the company's future, while the stock is currently trading 4.8% above its 20-day simple moving average.
  • Earnings Outlook: Organigram is set to provide its next financial update on May 11, 2026, with EPS estimates dropping from 22 cents to a loss of 1 cent, while revenue estimates are expected to rise from CAD 45.70 million to CAD 54.67 million, indicating potential value opportunities.
seekingalpha
8.5
02-19seekingalpha
British American Tobacco Invests C$65.2M in Organigram Acquisition
  • Investment Scale: British American Tobacco's C$65.2M private placement for Organigram's Sanity Group acquisition underscores its commitment to emerging markets, likely enhancing Organigram's competitive position.
  • Share Subscription: Under the agreement, BAT will subscribe to approximately 14.02 million Organigram shares at C$3.00 each, generating about C$42.1M, which will further solidify its equity stake in Organigram.
  • Use of Funds: The proceeds from this financing will be combined with existing cash and up to C$60M in credit facilities from ATB Financial to fund the cash portion of the Sanity acquisition and cover transaction costs, ensuring a smooth acquisition process.
  • Market Reaction: Organigram's shares rose by 4.35% in premarket trading, reflecting positive market sentiment towards this investment and acquisition plan, which may enhance the company's long-term growth potential.
Wall Street analysts forecast OGI stock price to rise
2 Analyst Rating
Wall Street analysts forecast OGI stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.36
Averages
2.64
High
2.91
Current: 0.000
sliders
Low
2.36
Averages
2.64
High
2.91
Canaccord
Buy
maintain
$3 -> $4
AI Analysis
2026-02-19
Reason
Canaccord
Price Target
$3 -> $4
AI Analysis
2026-02-19
maintain
Buy
Reason
Canaccord raised the firm's price target on Organigram to C$4 from C$3 and keeps a Buy rating on the shares.
Canaccord
Buy
initiated
$3
2026-01-27
Reason
Canaccord
Price Target
$3
2026-01-27
initiated
Buy
Reason
Canaccord initiated coverage of Organigram with a Buy rating and C$3 price target. The firm says that despite regulatory headwinds and structural inefficiencies, the Canadian cannabis market "remains a global benchmark for legal cannabis commercialization." Organigram is accelerating its transition a vertically integrated global cannabis company, with market leading positions including the number one share in pre-rolls, concentrates and milled flower, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OGI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Organigram Global Inc (OGI.O) is 173.00, compared to its 5-year average forward P/E of -13.43. For a more detailed relative valuation and DCF analysis to assess Organigram Global Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.43
Current PE
173.00
Overvalued PE
24.07
Undervalued PE
-50.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-23.85
Current EV/EBITDA
10.30
Overvalued EV/EBITDA
225.96
Undervalued EV/EBITDA
-273.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.86
Current PS
1.04
Overvalued PS
5.79
Undervalued PS
-0.08

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stock under $5 should I buy today?
Intellectia · 56 candidates
Market Cap: >= 100.00MRegion: USPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 5.0%List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
API logo
API
Agora Inc
431.16M
IOVA logo
IOVA
Iovance Biotherapeutics Inc
1.58B
GOGO logo
GOGO
Gogo Inc
599.67M
IMPP logo
IMPP
Imperial Petroleum Inc
188.03M
OCGN logo
OCGN
Ocugen Inc
608.82M
TRON logo
TRON
TRON Inc
359.44M
stocks under 10 expected to gap up today
Intellectia · 26 candidates
Price: $1.00 - $10.00Volume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEGap Pattern: GapUpPre Market Price Change: >= $3.00
Ticker
Name
Market Cap$
top bottom
JZXN logo
JZXN
Jiuzi Holdings Inc
1.66M
CDIO logo
CDIO
Cardio Diagnostics Holdings Inc
3.89M
BOXL logo
BOXL
Boxlight Corp
1.24M
TALK logo
TALK
Talkspace Inc
651.03M
ELAB logo
ELAB
PMGC Holdings Inc
1.46M
MOB logo
MOB
Mobilicom Ltd
58.61M
best penny stock to invest in
Intellectia · 28 candidates
Market Cap: 50.00M - 2.00BPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 10.0%Net Margin: >= 0.01List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
BTCS logo
BTCS
BTCS Inc
74.02M
CPSH logo
CPSH
CPS Technologies Corp
84.14M
NIU logo
NIU
NIU Technologies
262.74M
AKBA logo
AKBA
Akebia Therapeutics Inc
313.13M
OGI logo
OGI
Organigram Global Inc
186.49M
PAYS logo
PAYS
Paysign Inc
179.99M
penny stocks with great upside
Intellectia · 54 candidates
Market Cap: 50.00M - 1.50BPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 20.0%List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
TCRX logo
TCRX
TScan Therapeutics Inc
55.18M
XTIA logo
XTIA
XTI Aerospace Inc
56.59M
BWEN logo
BWEN
Broadwind Inc
56.61M
UPXI logo
UPXI
Upexi Inc
56.94M
BTM logo
BTM
Bitcoin Depot Inc
58.90M
AMPG logo
AMPG
Amplitech Group Inc
70.51M
good penny stocks to invest in
Intellectia · 32 candidates
Market Cap: <= 500.00MPrice: <= $5.00Quarter Revenue Yoy Growth: >= 10.0%Beta: HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CAN logo
CAN
Canaan Inc
498.64M
ORGO logo
ORGO
Organogenesis Holdings Inc
487.34M
CERS logo
CERS
Cerus Corp
485.98M
OCGN logo
OCGN
Ocugen Inc
465.36M
API logo
API
Agora Inc
402.42M
NNDM logo
NNDM
Nano Dimension Ltd
395.43M
Best stock under 3.50 that will 3x
Intellectia · 29 candidates
Market Cap: <= 2.00BPrice: <= $3.50Beta: HighRiskRevenue 5yr Cagr: >= 20Annual Eps Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
CLVT logo
CLVT
Clarivate PLC
1.86B
BITF logo
BITF
Bitfarms Ltd
1.61B
BLND logo
BLND
Blend Labs Inc
732.49M
SNDL logo
SNDL
SNDL Inc
406.85M
LCTX logo
LCTX
Lineage Cell Therapeutics Inc
382.34M
SLQT logo
SLQT
SelectQuote Inc
283.31M

Whales Holding OGI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Organigram Global Inc (OGI) stock price today?

The current price of OGI is 1.44 USD — it has increased 0

What is Organigram Global Inc (OGI)'s business?

Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd.

What is the price predicton of OGI Stock?

Wall Street analysts forecast OGI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGI is2.64 USD with a low forecast of 2.36 USD and a high forecast of 2.91 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Organigram Global Inc (OGI)'s revenue for the last quarter?

Organigram Global Inc revenue for the last quarter amounts to 63.54M USD, increased 48.70

What is Organigram Global Inc (OGI)'s earnings per share (EPS) for the last quarter?

Organigram Global Inc. EPS for the last quarter amounts to 0.15 USD, decreased -175.00

How many employees does Organigram Global Inc (OGI). have?

Organigram Global Inc (OGI) has 1139 emplpoyees as of March 11 2026.

What is Organigram Global Inc (OGI) market cap?

Today OGI has the market capitalization of 194.60M USD.